Tibet Cheezheng Tibetan Medicine (002287) Fundamentals 2026 — P/E 17.0x, Revenue Analysis | SniperIQ
Tibet Cheezheng Tibetan Medicine (002287) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥11.8B, trading at ¥20.63 on the SHZ. This SniperIQ fundamentals page covers Tibet Cheezheng Tibetan Medicine's valuation (P/E 17.0x, P/B 2.3x), profitability (net margin 27.5%), revenue (¥2.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tibet Cheezheng Tibetan Medicine's market cap?
Tibet Cheezheng Tibetan Medicine (002287) has a market capitalization of approximately ¥11.8B, trading at ¥20.63 on the SHZ. Market cap moves with the live share price.
What is Tibet Cheezheng Tibetan Medicine's P/E ratio?
Tibet Cheezheng Tibetan Medicine's trailing twelve-month P/E ratio is 17.0x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tibet Cheezheng Tibetan Medicine?
Tibet Cheezheng Tibetan Medicine runs a net profit margin of 27.5%, a gross margin of 100.4%, and an operating margin of 32.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tibet Cheezheng Tibetan Medicine generate?
Tibet Cheezheng Tibetan Medicine reported revenue of ¥2.4B for fiscal year 2025, with net income of ¥646M and earnings per share (EPS) of 1.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tibet Cheezheng Tibetan Medicine pay a dividend?
Tibet Cheezheng Tibetan Medicine offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tibet Cheezheng Tibetan Medicine financially healthy?
Tibet Cheezheng Tibetan Medicine carries a debt-to-equity ratio of 0.16x and a current ratio of 3.12x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tibet Cheezheng Tibetan Medicine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tibet Cheezheng Tibetan Medicine (002287) the key facts are: market cap ¥11.8B, P/E 17.0x, revenue ¥2.4B, 52-week range 18.33-38.16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tibet Cheezheng Tibetan Medicine's full fundamentals live
Get Tibet Cheezheng Tibetan Medicine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.